Gigagen, Inc.
SOUTH SAN FRANCISCO, CA · CIK 0001708610 · Biotech · Private
Recombinant intravenous immunoglobulin (rIVIg) produced via GigaLink molecular genomics technology and CHO cell expression
gigagen.com →- Grants
- $9.7M
- 14 awards
- Sector median: 1
- Raised
- $36M
- 1 Form D · Jul 2017
- 111 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 24 granted · 16 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Recombinant Hyperimmune Gammaglobulin for Pneumococcal Disease | $224,819 | |
| Federal grant | Department of Health and Human Services · Phase II · Molecular Kits and Software for Lymphoid Malignancy Work-ups | $256,506 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · An Advanced Tool for Immune Cell Analysis Using Microfluidics | $225,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Production Technology for Recombinant Intravenous Immunoglobulin | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Cloud-Based Bioinformatics for Immune Repertoire Analysis | $5,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Commercialization of an Advanced Technology for T Cell Receptor Analysis and Engineering | $40,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency | $750,198 | |
| Federal grant | Department of Health and Human Services · Phase II · Next-Generation Antibody Discovery and Development Technology | $1,570,238 | |
| Federal grant | Department of Health and Human Services · Phase II · Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency | $749,659 | |
| Private capital raised | Form D · SEC | $36,126,542 | |
| Federal grant | Department of Health and Human Services · Phase II · Production Technology for Recombinant Intravenous Immunoglobulin | $3,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Next-Generation Antibody Discovery and Development Technology | $480,577 | |
| Federal grant | Department of Health and Human Services · Phase II · Production Technology for Recombinant Intravenous Immunoglobulin | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Next-Generation Antibody Discovery and Development Technology | $209,825 | |
| Federal grant | Department of Health and Human Services · Phase II · Production Technology for Recombinant Intravenous Immunoglobulin | $1,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1204 | PLAKOUS THERAPEUTICS, INC. | — | $185K |
| 1205 | ADIAL PHARMACEUTICALS, INC. | — | $38M |
| 1206 | FORWARD DEFENSE, LLC | — | — |
| 1207 | Gigagen, Inc. | — | $36M |
| 1208 | Kodiak Sciences Inc. | — | $36M |
| 1209 | MIRNATECH INTERNATIONAL, INC. | — | — |
| 1210 | VIVASC THERAPEUTICS INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- David JohnsonDirector · Executive Officer
- Carter KellerDirector
- Chuck WilsonDirector
Patents
- Recombinant Polyclonal Proteins Targeting Hepatitis B Virus (hbv) And Methods Of Use Thereofapplication
- Methods Of Analyzing Recombinant Polyclonal Proteinsapplication
- Anti-CTLA-4 Binding Proteins and Methods of Use Thereofapplication
- Recombinant Polyclonal Proteins and Methods of Use Thereofgranted
- Recombinant Polyclonal Proteins Targeting COVID-19 And Methods Of Use Thereofapplication
- Anti-CTLA-4 Binding Proteins and Methods of Use Thereofgranted
- Anti-CTLA-4 Binding Proteins and Methods of Use Thereofapplication
- Recombinant Polyclonal Proteins Targeting COVID-19 And Methods Of Use Thereofgranted
- Recombinant Fusion Proteins and Libraries from Immune Cell Repertoiresapplication
- Recombinant Fusion Proteins and Libraries from Immune Cell Repertoiresgranted
- Systems And Methods For Massively Parallel Combinatorial Analysis Of Single Cellsgranted
- System And Method For Massively Parallel Analysis For Nucleic Acids In Single Cellsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.